Brimonidine 4857534 216705889 2008-06-02T21:05:39Z Crk2002 3704296 {{drugbox | IUPAC_name = 5-Bromo-''N''-(4,5-dihydro-1''H''-imidazol-2-yl) quinoxalin-6-amine | width=260 | image = Brimonidine structure.png | CAS_number = 59803-98-4 | ATC_prefix = S01 | ATC_suffix = EA05 | ATC_supplemental = | PubChem = 2435 | DrugBank = APRD00034 | C=11 | H=10 | Br=1 | N=5 | molecular_weight = 292.135 g/mol | bioavailability = | protein_bound = | metabolism = liver primarily | elimination_half-life = 3 hours | pregnancy_category = B | legal_status = unknown | routes_of_administration = Ocular, 1 gtt }} '''Brimonidine''' (bri-MOE-ni-deen, brand names Alphagan and Alphagan-P) is a [[medication|drug]] used to treat [[glaucoma|open-angle glaucoma]] or [[ocular hypertension]]. Alphagan is also used to induce [[miosis]] for people suffering from poor night vision after Lasik or PRK surgery. It acts via decreasing synthesis of [[aqueous humor]], and increasing the amount that drains from the eye. As a treatment for glaucoma, it is usually given in eyedrop form. Brimonidine is an α<sub>2</sub>-adrenergic receptor agonist. Alpha 2 agonists, through the activation of the Gi GPCR, inhibit the production of AC. This reduces cAMP and hence Aqueous Humour production by the ciliary body. ==Clinical uses== Brimonidine is indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. ==External links== * [http://www.alphaganp.com/ Alphagan P product website] * [http://www.alphaganp.com/ALPHGANP.pdf Alphagan P prescribing information] ==References== * ''Mosby's Drug Guide for Nurses'' (7th edition; Skidmore) 2007. {{Antiglaucoma preparations and miotics}} [[Category:Imidazolines]] [[Category:Quinoxalines]]